Fig. 2From: Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical developmentTreatment-related adverse events associated with 2-week on/1-week off anlotinib 12 mg/day. Adverse events reported in all patients (n = 21) in a phase I trial [21]. HFS hand-foot skin reaction, ALT alanine aminotransferase, ME myocardial enzymesBack to article page